US · NMRA · BIOTECHNOLOGY
Neumora Therapeutics, Inc. Common Stock (NMRA) intrinsic value and stock valuation
$0.33as of 2026-11-21 · Mkt cap 298.31M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Neumora Therapeutics, Inc. Common Stock DCF and intrinsic value
InvestorsCraft values NMRA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NMRA’s statements →
Neumora Therapeutics, Inc. Common Stock Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2020–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-241.16M | -$-263.46M | -$-188.19M | -$-135.87M | -$-237.32M |
| Net income | -$-236.93M | -$-243.79M | -$-235.93M | -$-130.9M | -$-237.31M |
| EPSd | -$-1.45M | -$-1.53M | -$-1.49M | -$-861.47K | -$-1.56M |
| Operating cash flow | -$-206.44M | -$-182.94M | -$-163.28M | -$-114.9M | -$-75.42M |
| Capital expenditure | $0.00 | $0.00 | -$-120K | -$-510K | -$-820K |
| Free cash flow | -$-206.44M | -$-182.94M | -$-163.4M | -$-115.41M | -$-76.24M |
| Total assets | $191.1M | $317M | $496.2M | $426.2M | $429.3M |
| Total debt | $480K | $1.85M | $5.23M | $8.44M | $2.05M |
| Net debt | -$-182.05M | -$-140.29M | -$-368.81M | -$-232.5M | -$-407.19M |
| Total equity | $103.9M | $287.1M | $469.1M | -$-446.85M | -$-325.22M |
| Cash and short-term investments | $182.5M | $307.6M | $454M | $371.9M | $409.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $5M | $0.00 | $670K | $0.00 | $0.00 |
| Gross profit | -$-5M | $0.00 | -$-670K | $0.00 | $0.00 |
| Research and development expenses | $176.1M | $200.9M | $142.7M | $104.8M | $212.8M |
| Selling, general and administrative expenses | $60.1M | $62.5M | $44.8M | $31.1M | $24.6M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $236.2M | $263.5M | $187.5M | $135.9M | $237.3M |
| Cost and expenses | $241.2M | $263.5M | $188.2M | $135.9M | $237.3M |
| Interest income | $8.34M | $19.9M | $16.6M | $4.56M | $0.00 |
| Interest expense | $3.22M | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $210K | $630K | $670K | $590K | $540K |
| Ebitda | -$-233.37M | -$-242.98M | -$-234.99M | -$-130.31M | -$-236.77M |
| Operating income | -$-241.16M | -$-263.46M | -$-188.19M | -$-135.87M | -$-237.32M |
| Total other income/expenses, net | $4.36M | $19.9M | -$-47.46M | $4.97M | $10K |
| Income before tax | -$-236.8M | -$-243.61M | -$-235.66M | -$-130.9M | -$-237.31M |
| Income tax expense | $130K | $180K | $270K | $0.00 | $0.00 |
| Net income | -$-236.93M | -$-243.79M | -$-235.93M | -$-130.9M | -$-237.31M |
| Weighted average shares outstanding | $163.4M | $159.4M | $158.8M | $152M | $152M |
| Weighted average diluted shares outstanding | $163.4M | $159.4M | $158.8M | $152M | $152M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $182.5M | $307.6M | $454M | $371.9M | $409.3M |
| Net receivables | $0.00 | $0.00 | $940K | $920K | $200K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $190.5M | $314.1M | $478.3M | $388M | $415.6M |
| Property, plant and equipment, net | $460K | $2.92M | $6.86M | $10.6M | $4.04M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $9.85M | $23.5M | $0.00 |
| Total non-current assets | $510K | $2.92M | $17.9M | $38.3M | $13.7M |
| Total assets | $191.1M | $317M | $496.2M | $426.2M | $429.3M |
| Accounts payable | $3.38M | $3.31M | $340K | $7.15M | $1.64M |
| Short-term debt | $280K | $1.85M | $3.38M | $3.37M | $1.06M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $32.5M | $29.9M | $25.1M | $23.7M | $23.3M |
| Long-term debt | $190K | $0.00 | $1.85M | $5.07M | $1M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $54.7M | $20K | $2.01M | $849.4M | $731.2M |
| Capital lease obligations | $0.00 | $1.85M | $5.23M | $8.44M | $2.05M |
| Total liabilities | $87.2M | $29.9M | $27.1M | $873.1M | $754.5M |
| Common stock | $20K | $20K | $20K | $0.00 | $0.00 |
| Retained earnings | -$-1.18B | -$-947.22M | -$-703.43M | -$-467.51M | -$-336.61M |
| Accumulated other comprehensive income (loss) | $0.00 | $60K | -$-80K | -$-770K | $0.00 |
| Total equity | $103.9M | $287.1M | $469.1M | -$-446.85M | -$-325.22M |
| Total investments | $0.00 | $165.4M | $89.8M | $154.5M | $0.00 |
| Total debt | $480K | $1.85M | $5.23M | $8.44M | $2.05M |
| Net debt | -$-182.05M | -$-140.29M | -$-368.81M | -$-232.5M | -$-407.19M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-236.93M | -$-243.79M | -$-235.93M | -$-130.9M | -$-237.31M |
| Depreciation and amortization | $210K | $630K | $670K | $590K | $540K |
| Stock-based compensation | $29.9M | $40M | $17.2M | $8.3M | $4.27M |
| Change in working capital | -$-440K | $22.6M | -$-8.9M | -$-6.95M | -$-960K |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $70K | $2.87M | -$-580K | -$-1.25M | -$-760K |
| Net cash provided by operating activities | -$-206.44M | -$-182.94M | -$-163.28M | -$-114.9M | -$-75.42M |
| Investments in property, plant and equipment | $0.00 | $0.00 | -$-120K | -$-510K | -$-820K |
| Acquisitions, net | $0.00 | -$-780K | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $168.5M | -$-70.56M | $64.4M | -$-168.01M | -$-820K |
| Common stock issued | $19.9M | $13.7M | $233.4M | $0.00 | $960K |
| Common stock repurchased | $0.00 | $0.00 | -$-490K | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $77.1M | $21.6M | $231.9M | $115.7M | $293.5M |
| Net change in cash | $39.2M | -$-231.89M | $133M | -$-167.17M | $217.3M |
| Cash at end of period | $182.5M | $143.4M | $375.3M | $242.2M | $409.4M |
| Operating cash flow | -$-206.44M | -$-182.94M | -$-163.28M | -$-114.9M | -$-75.42M |
| Capital expenditure | $0.00 | $0.00 | -$-120K | -$-510K | -$-820K |
| Free cash flow | -$-206.44M | -$-182.94M | -$-163.4M | -$-115.41M | -$-76.24M |
Line items
Line items
Line items
About Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
- CEO
- Paul L. Berns
- Employees
- 96
- Beta
- 2.77
Explore
Frequently asked questions
What is the intrinsic value of Neumora Therapeutics, Inc. Common Stock (NMRA)?
InvestorsCraft does not currently publish an intrinsic value for NMRA. How the IC value is calculated.
Is NMRA undervalued?
InvestorsCraft does not publish an undervaluation signal for NMRA at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.